Peptide vectors for gene delivery: From single peptides to multifunctional peptide nanocarriers

Nanomedicine

Volumn 9, Issue 14, 2014, Pages 2217-2232

  De Raad, Markus ^a   Teunissen, Erik A ^a   Mastrobattista, Enrico ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cationic peptides; Cell penetrating peptides; DNA condensing peptides; Fusion peptides; Nanocarriers; Nonviral gene delivery; Peptide guided gene delivery; Protein engineering

Indexed keywords

CELL PENETRATING PEPTIDE; GENE THERAPY AGENT; NANOCARRIER; PEPTIDE NUCLEIC ACID; PEPTIDE VECTOR; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; NANOMATERIAL; PEPTIDE;

CELL SPECIFICITY; CELL TRANSPORT; CHEMICAL MODIFICATION; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; PEPTIDE LIBRARY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; CHEMISTRY; GENE VECTOR; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; GENETIC VECTORS; MOLECULAR SEQUENCE DATA; NANOSTRUCTURES; PEPTIDES;

EID: 84911475819     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.14.90     Document Type: Review

References (124)

1. Jang JH, Lim KI, Schaffer DV. Library selection and directed evolution approaches to engineering targeted viral vectors. Biotechnol. Bioeng. 98(3), 515-524 (2007).
2. Glover DJ. Artificial viruses: exploiting viral trafficking for therapeutics. Infect. Disord. Drug Targets 12(1), 68-80 (2012).
3. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12(5), 341-355 (2011).
4. Mastrobattista E, van der Aa MA, Hennink WE, Crommelin DJ. Artificial viruses: a nanotechnological approach to gene delivery. Nat. Rev. Drug Discov. 5(2), 115-121 (2006).
5. Read ML, Logan A, Seymour LW. Barriers to gene delivery using synthetic vectors. Adv. Genet. 53, 19-46 (2005).
6. Burke RS, Pun SH. Extracellular barriers to in vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjug. Chem. 19(3), 693-704 (2008).
7. Dauty E, Verkman AS. Actin cytoskeleton as the principal determinant of size-dependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J. Biol. Chem. 280(9), 7823-7828 (2005).
8. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54(5), 715-758 (2002).
9. van der Aa MA, Mastrobattista E, Oosting RS, Hennink WE, Koning GA, Crommelin DJ. The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm. Res. 23(3), 447-459 (2006).
10. Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Targeted delivery to the nucleus. Adv. Drug Deliv. Rev. 59(8), 698-717 (2007).
11. Talcott B, Moore MS. Getting across the nuclear pore complex. Trends Cell Biol. 9(8), 312-318 (1999).
12. Pante N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol. Biol. Cell 13(2), 425-434 (2002).
13. Hsu CYM, Uludag H. Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. J. Drug Target. 20(4), 301-328 (2012).
14. Pezzoli D, Candiani G. Non-viral gene delivery strategies for gene therapy: a "ménage à trois" among nucleic acids, materials, and the biological environment: stimuli-responsive gene delivery vectors. J. Nanoparticle Res. 15(3), 1 (2013).
15. Saccardo P, Villaverde A, Gonzalez-Montalban N. Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol. Adv. 27(4), 432-438 (2009).
16. Miyata K, Nishiyama N, Kataoka K. Rational design of smart supramolecular assemblies for gene delivery: Chemical challenges in the creation of artificial viruses. Chem. Soc. Rev. 41(7), 2562-2574 (2012).
17. Hoyer J, Neundorf I. Peptide vectors for the nonviral delivery of nucleic acids. Acc. Chem. Res. 45(7), 1048-1056 (2012).
18. Mann A, Thakur G, Shukla V, Ganguli M. Peptides in DNA delivery: current insights and future directions. Drug Discov. Today 13(3-4), 152-160 (2008).
19. Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotechnol. 17(6), 638-642 (2006).
20. Kharidia R, Friedman KA, Liang JF. Improved gene expression using low molecular weight peptides produced from protamine sulfate. Biochemistry Mosc. 73(10), 1162-1168 (2008).
21. El-Mousawi M, Tchistiakova L, Yurchenko L et al. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. J. Biol. Chem. 278(47), 46681-46691 (2003).
22. Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl Acad. Sci. USA 89(17), 7934-7938 (1992).
23. Midoux P, Mendes C, Legrand A et al. Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res. 21(4), 871-878 (1993).
24. Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. Int. J. Mol. Sci. 9(7), 1276-1320 (2008).
25. Rennert R, Neundorf I, Beck-Sickinger AG. Calcitonin-derived peptide carriers: mechanisms and application. Adv. Drug Deliv. Rev. 60(4-5), 485-498 (2008).
26. Schaffert D, Badgujar N, Wagner E. Novel Fmoc-polyamino acids for solid-phase synthesis of defined polyamidoamines. Org. Lett. 13(7), 1586-1589 (2011).
27. Martin ME, Rice KG. Peptide-guided gene delivery. AAPSa J. 9(1), E18-E29 (2007).
28. Lehto T, Simonson OE, Mäger I et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol. Ther. 19(8), 1457-1467 (2011).
29. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG. Stability of peptide-condensed plasmid DNA formulations. J. Pharm. Sci. 87(6), 678-683 (1998).
30. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release 121(1-2), 64-73 (2007).
31. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 61(9), 704-709 (2009).
32. Plank C, Tang MX, Wolfe AR, Szoka FC Jr. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum. Gene Ther. 10(2), 319-332 (1999).
33. Gottschalk S, Sparrow JT, Hauer J et al. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther. 3(5), 448-457 (1996).
34. Aris A, Villaverde A. Modular protein engineering for nonviral gene therapy. Trends Biotechnol. 22(7), 371-377 (2004).
35. Schwartz B, Ivanov MA, Pitard B et al. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo. Gene Ther. 6(2), 282-292 (1999).
36. Tecle M, Preuss M, Miller AD. Kinetic study of DNA condensation by cationic peptides used in nonviral gene therapy: analogy of DNA condensation to protein folding. Biochemistry (NY) 42(35), 10343-10347 (2003).
37. McKenzie DL, Kwok KY, Rice KG. A potent new class of reductively activated peptide gene delivery agents. J. Biol. Chem. 275(14), 9970-9977 (2000).
38. McKenzie DL, Smiley E, Kwok KY, Rice KG. Low molecular weight disulfide cross-linking peptides as nonviral gene delivery carriers. Bioconjug. Chem. 11(6), 901-909 (2000).
39. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339(6122), 971-975 (2013).
40. Khalil IA, Futaki S, Niwa M et al. Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther. 11(7), 636-644 (2004).
41. Lehto T, Abes R, Oskolkov N et al. Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J. Control. Release 141(1), 42-51 (2010).
42. Yin H, Moulton HM, Seow Y et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17(24), 3909-3918 (2008).
43. Langedijk JP. Translocation activity of C-terminal domain of pestivirus Erns and ribotoxin L3 loop. J. Biol. Chem. 277(7), 5308-5314 (2002).
44. Kichler A, Leborgne C, Marz J, Danos O, Bechinger B. Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc. Natl Acad. Sci. USA 100(4), 1564-1568 (2003).
45. Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J. Biol. Chem. 269(17), 12918-12924 (1994).
46. Rittner K, Benavente A, Bompard-Sorlet A et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol. Ther. 5(2), 104-114 (2002).
47. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry (NY) 41(48), 14150-14157 (2002).
48. Takeshima K, Chikushi A, Lee KK, Yonehara S, Matsuzaki K. Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J. Biol. Chem. 278(2), 1310-1315 (2003).
49. Midoux P, Kichler A, Boutin V, Maurizot JC, Monsigny M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug. Chem. 9(2), 260-267 (1998).
50. Read ML, Singh S, Ahmed Z et al. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 33(9), 1-16 (2005).
51. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC Jr. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry (NY) 36(10), 3008-3017 (1997).
52. Baru M, Nahum O, Jaaro H, Sha'anani J, Nur I. Lysosome-disrupting peptide increases the efficiency of in-vivo gene transfer by liposome-encapsulated DNA. J. Drug Target. 6(3), 191-199 (1998).
53. Ignatovich IA, Dizhe EB, Pavlotskaya AV et al. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J. Biol. Chem. 278(43), 42625-42636 (2003).
54. Fischer PM, Zhelev NZ, Wang S, Melville JE, Fahraeus R, Lane DP. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Pept. Res. 55(2), 163-172 (2000).
55. Lehto T, Kurrikoff K, Langel Ã. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv. 9(7), 823-836 (2012).
56. Lehto T, Ezzat K, Langel U. Peptide nanoparticles for oligonucleotide delivery. Prog. Mol. Biol. Trans. Sci. 104, 397-426 (2011).
57. El Andaloussi S, Lehto T, Mäger I et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39(9), 3972-3987 (2011).
58. Mäe M, EL Andaloussi S, Lundin P et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release 134(3), 221-227 (2009).
59. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31(11), 2717-2724 (2003).
60. Deshayes S, Konate K, Rydström A et al. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. Small 8(14), 2184-2188 (2012).
61. Schaffert D, Troiber C, Wagner E. New sequence-defined polyaminoamides with tailored endosomolytic properties for plasmid DNA delivery. Bioconjug. Chem. 23(6), 1157-1165 (2012).
62. Vázquez E, Ferrer-Miralles N, Villaverde A. Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov. Today 13(23-24), 1067-1074 (2008).
63. Cohen RN, Rashkin MJ, Wen X, Szoka FC Jr. Molecular motors as drug delivery vehicles. Drug Discov. Today 2(1), 111-118 (2005).
64. Pigeon L, Gonc¸alves C, Gosset D, Pichon C, Midoux P. An E3-14.7K peptide that promotes microtubules-mediated transport of plasmid DNA increases polyplexes transfection efficiency. Small 9(22), 3845-3851 (2013).
65. Moseley GW, Roth DM, DeJesus MA et al. Dynein light chain association sequences can facilitate nuclear protein import. Mol. Biol. Cell 18(8), 3204-3213 (2007).
66. Tanaka K, Kanazawa T, Sugawara K, Horiuchi S, Takashima Y, Okada H. A cytoplasm-sensitive peptide vector cross-linked with dynein light chain association sequence (DLCAS) enhances gene expression. Int. J. Pharm. 419(1-2), 231-234 (2011).
67. Aris A, Villaverde A. Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem. Biophys. Res. Commun. 304(4), 625-631 (2003).
68. Belting M, Sandgren S, Wittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv. Drug Deliv. Rev. 57(4), 505-527 (2005).
69. Wagstaff KM, Jans DA. Nucleocytoplasmic transport of DNA: enhancing non-viral gene transfer. Biochem. J. 406(2), 185-202 (2007).
70. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther. 9(3), 157-167 (2002).
71. van der Aa MAEM, Koning GA, d'Oliveira C et al. An NLS peptide covalently linked to linear DNA does not enhance transfection efficiency of cationic polymer based gene delivery systems. J. Gene Med. 7(2), 208-217 (2005).
72. Remaut K, Symens N, Lucas B, Demeester J, De Smedt SC. Cell division responsive peptides for optimized plasmid DNA delivery: the mitotic window of opportunity? J. Control. Release 179(0), 1-9 (2014).
73. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
74. Schatzlein AG. Targeting of synthetic gene delivery systems. J. Biomed. Biotechnol. 2003(2), 149-158 (2003).
75. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41(7), 2971-3010 (2012).
76. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur. J. Cancer 43(8), 1242-1250 (2007).
77. Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39-43 (2007).
78. Levine RM, Scott CM, Kokkoli E. Peptide functionalized nanoparticles for nonviral gene delivery. Soft Matter 9(4), 985-1004 (2013).
79. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist. Updat. 6(6), 363-371 (2003).
80. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm. 4(5), 631-651 (2007).
81. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 1786(2), 126-138 (2008).
82. Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 262(36), 17294-17298 (1987).
83. Dijkgraaf I, Kruijtzer JAW, Liu S et al. Improved targeting of the avÃY3 integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34(2), 267-273 (2007).
84. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl Acad. Sci. USA 99(11), 7444-7449 (2002).
85. Alberici L, Roth L, Sugahara KN et al. De novo design of a tumor-penetrating peptide. Cancer Res. 73(2), 804-812 (2013).
86. Sugahara KN, Teesalu T, Prakash Karmali P et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031-1035 (2010).
87. Sugahara KN, Teesalu T, Karmali PP et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6), 510-520 (2009).
88. Steele JC, Rao A, Marsden JR et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther. 18(6), 584-593 (2011).
89. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25(14), 2730-2736 (1997).
90. Wang Y, Mangipudi SS, Canine BF, Hatefi A. A designer biomimetic vector with a chimeric architecture for targeted gene transfer. J. Control. Release 137(1), 46-53 (2009).
91. Rajagopalan R, Xavier J, Rangaraj N, Rao NM, Gopal V. Recombinant fusion proteins TAT-Mu, Mu and Mu-Mu mediate efficient non-viral gene delivery. J. Gene Med. 9(4), 275-286 (2007).
92. Govindarajan S, Sivakumar J, Garimidi P et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials 33(8), 2570-2582 (2012).
93. Wang HY, Chen JX, Sun YX et al. Construction of cell penetrating peptide vectors with N-terminal stearylated nuclear localization signal for targeted delivery of DNA into the cell nuclei. J. Control. Release 155(1), 26-33 (2011).
94. Guo XD, Wiradharma N, Liu SQ et al. Oligomerized alpha-helical KALA peptides with pendant arms bearing cell-adhesion, DNA-binding and endosome-buffering domains as efficient gene transfection vectors. Biomaterials 33(26), 6284-6291 (2012).
95. Xavier J, Singh S, Dean DA, Rao NM, Gopal V. Designed multi-domain protein as a carrier of nucleic acids into cells. J. Control. Release 133(2), 154-160 (2009).
96. Fortunati E, Ehlert E, van Loo ND et al. A multi-domain protein for beta1 integrin-targeted DNA delivery. Gene Ther. 7(17), 1505-1515 (2000).
97. Box M, Parks DA, Knight A, Hale C, Fishman PS, Fairweather NF. A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J. Drug Target. 11(6), 333-343 (2003).
98. Canine BF, Wang Y, Hatefi A. Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency. J. Control. Release 129(2), 117-123 (2008).
99. Gao P, Li X, Liu Y et al. Construction, expression and characterization of a chimeric multi-domain protein mediating specific DNA transfer. Protein Expr. Purif. 74(2), 189-195 (2010).
100. Fominaya J, Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein: Novel non-viral gene delivery system. J. Biol. Chem. 271(18), 10560-10568 (1996).
101. Gaur R, Gupta PK, Goyal A, Wels W, Singh Y. Delivery of nucleic acid into mammalian cells by anthrax toxin. Biochem. Biophys. Res. Commun. 297(5), 1121-1127 (2002).
102. Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 8(23), 1753-1761 (2001).
103. Kim ES, Yang SW, Hong DK, Kim WT, Kim HG, Lee SK. Cell-penetrating DNA-binding protein as a safe and efficient naked DNA delivery carrier in vitro and in vivo. Biochem. Biophys. Res. Commun. 392(1), 9-15 (2010).
104. Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23(6), 709-717 (2005).
105. Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 8(9), 2674-2683 (2009).
106. Eguchi A, Meade BR, Chang YC et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27(6), 567-571 (2009).
107. Fritz JD, Herweijer H, Zhang G, Wolff JA. Gene transfer into mammalian cells using histone-condensed plasmid DNA. Hum. Gene Ther. 7(12), 1395-1404 (1996).
108. Zhang T, Wang CY, Zhang W et al. Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine. Vaccine 28(23), 3949-3955 (2010).
109. Fominaya J, Uherek C, Wels W. A chimeric fusion protein containing transforming growth factor-a mediates gene transfer via binding to the EGF receptor. Gene Ther. 5(4), 521-530 (1998).
110. Uherek C, Fominaya J, Wels W. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. J. Biol. Chem. 273(15), 8835-8841 (1998).
111. Glover DJ, Su MN, Mechler A, Martin LL, Jans DA. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells. FASEB J. 23(9), 2996-3006 (2009).
112. Canine BF, Wang Y, Hatefi A. Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J. Control. Release 138(3), 188-196 (2009).
113. Mangipudi SS, Canine BF, Wang Y, Hatefi A. Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol. Pharm. 6(4), 1100-1109 (2009).
114. Chen X, Zaro JL, Shen W. Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev. 65(10), 1357-1369 (2013).
115. Anderson JC, Dueber JE, Leguia M et al. BglBricks: a flexible standard for biological part assembly. J. Biol. Eng. 4(1), 1 (2010).
116. de Raad M, Kooijmans SA, Teunissen EA, Mastrobattista E. A solid-phase platform for combinatorial and scarless multipart gene assembly. ACS Synth. Biol. 2(6), 316-326 (2013).
117. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S. A modular cloning system for standardized assembly of multigene constructs. PLoS ONE 6(2), e16765 (2011).
118. Lin C-, Moore PA, Auberry DL et al. Automated purification of recombinant proteins: combining high-throughput with high yield. Protein Expr. Purif. 47(1), 16-24 (2006).
119. De Raad M, Teunissen EA, Lelieveld D, Egan DA, Mastrobattista E. High-content screening of peptide-based non-viral gene delivery systems. J. Control. Release 158(3), 433-442 (2012).
120. Samuel SP, Jain N, O'Dowd F et al. Multifactorial determinants that govern nanoparticle uptake by human endothelial cells under flow. Int. J. Nanomedicine 7, 2943-2956 (2012).
121. Corradin G, Kajava AV, Verdini A. Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age. Sci. Trans. Med. 2(50) (2010).
122. Raibaut L, Ollivier N, Melnyk O. Sequential native peptide ligation strategies for total chemical protein synthesis. Chem. Soc. Rev. 41(21), 7001-7015 (2012).
123. Chandrudu S, Simerska P, Toth I. Chemical methods for peptide and protein production. Molecules 18(4), 4373-4388 (2013).
124. Lindgren J, Ekblad C, Abrahmsén L, Eriksson Karlström A. A native chemical ligation approach for combinatorial assembly of affibody molecules. Chembiochem 13(7), 1024-1031 (2012).